Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 1139-1143

  Tamura, Takayuki ^a   Shomori, Kohei ^a   Nakabayashi, Motoki ^a   Fujii, Nobuyuki ^a   Ryoke, Kazuo ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Oral carcinoma; Zoledronic acid

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BID; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL CYCLE; CELL PROLIFERATION; DIPHOSPHONATES; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; MOUTH NEOPLASMS; SALIVARY GLAND NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79952209985     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1152     Document Type: Article

References (29)

1. Momose F, Araida T, Negishi A, Ichijo H, Shioda S and Sasaki S: Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18: 391-395, 1989. (Pubitemid 20001923)
2. Sakai E and Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7: 927-933, 1992.
3. Parkin DM, Läärä E and Muir CS: Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41: 184-197, 1988.
4. Day GL and Blot WJ: Second primary tumors in patients with oral cancer. Cancer 70: 14-19, 1992.
5. Carvalho AL, Nishimoto IN, Califano JA and Kowalski LP: Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114: 806-816, 2004. (Pubitemid 40344442)
6. Jones AS, England J, Hamilton J, et al: Mandibular invasion in patients with oral and oropharyngeal squamous carcinoma. Clin Otolaryngol Allied Sci 22: 239-245, 1997. (Pubitemid 28344975)
7. Rao LP, Das SR, Mathews A, Naik BR, Chacko E and Pandey M: Mandibular invasion in oral squamous cell carcinoma: investigation by clinical examination and orthopantomogram. Int J Oral Maxillofac Surg 33: 454-457, 2004. (Pubitemid 38950212)
8. Okamoto M, Hiura K, Ohe G, et al: Mechanism for bone invasion of oral cancer cells mediated by interleukin-6 in vitro and in vivo. Cancer 89: 1966-1975, 2000.
9. Fleisch H: Bisphophonates: a new class of drugs in diseases of bone and calcium metabolism, recent results. Cancer Res 116: 1-28, 1989.
10. Green JR: Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 28: 4-10, 2001.
11. Rogers MJ, Watts DJ and Russell RG: Overview of bisphosphonates. Cancer 80: 1652-1660, 1997.
12. Nakajima H, Magae J, Tsuruga M, et al: Induction of mitochondria- dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett 253: 89-96, 2007. (Pubitemid 46874729)
13. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001. (Pubitemid 32685845)
14. Yuasa T, Nogawa M, Kimura S, et al: A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res 11: 853-859, 2005. (Pubitemid 40116914)
15. Matsumoto S, Kimura S, Segawa H, et al: Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47: 31-39, 2005. (Pubitemid 39643239)
16. Tewari M, Quan LT, O'Rourke K, et al: Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase, Cell 81: 801-809, 1995.
17. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ and Coxon FP: Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21: 684-694, 2006.
18. Van Beek E, Pieterman E, Cohen L, Löwik C and Papapoulos S: Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255: 491-494, 1999. (Pubitemid 29292287)
19. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K and Namiki M: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 169: 281-282, 2003. (Pubitemid 35461613)
20. Roninson IB: Tumor senescence as a determinant of drug response in vivo. Drug Resist Update 5: 204-208, 2002.
21. Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
22. Juan TS, McNiece IK, Argento JM, et al: Identification and mapping of Casp7, a cysteine protease resembling CPP32 beta, interleukin-1 beta converting enzyme, and CED-3. Genomics 40: 86-93, 1997. (Pubitemid 27108251)
23. Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129-1132, 1997. (Pubitemid 27097312)
24. Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-1136, 1997. (Pubitemid 27097313)
25. Sun J, Blaskovich MA, Knowles D, et al: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59: 4919-4926, 1999. (Pubitemid 29472897)
26. Karabulut B, Erten C, Gul MK, et al: Docetaxel/zoledronic acid combination triggers apoptosis synergistically through down-regulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 33: 239-246, 2009.
27. Murayama T, Kawasoe Y, Yamashita Y, et al: Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 28: 2147-2154, 2008.
28. Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126-1134, 2001. (Pubitemid 32448513)
29. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF and Soliani P: Zoledronic acid determines S-phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem Pharmacol 78: 133-141, 2009.